Penumbra (PEN) Net Income towards Common Stockholders Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -6.51% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 7.96% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -2.19% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 64.73% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 30.89% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 60.12% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 29.56% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn | 56.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.19% |
| Dec 31, 2025 | 130.20% |
| Sep 30, 2025 | 180.96% |
| Jun 30, 2025 | 142.60% |
| Mar 31, 2025 | 692.08% |
| Dec 31, 2024 | 49.89% |
| Sep 30, 2024 | 29.47% |
| Jun 30, 2024 | -109.92% |
| Mar 31, 2024 | -10.82% |
| Dec 31, 2023 | 104.47% |
| Sep 30, 2023 | 48.60% |
| Jun 30, 2023 | 54.43% |
| Mar 31, 2023 | 71.21% |
| Dec 31, 2022 | -26.03% |
| Sep 30, 2022 | -30.05% |
| Jun 30, 2022 | -30.61% |
| Mar 31, 2022 | -80.42% |
| Dec 31, 2021 | -80.87% |
| Sep 30, 2021 | 38.13% |
| Jun 30, 2021 | -14.72% |
| Mar 31, 2021 | 41.47% |
| Dec 31, 2020 | -11.28% |
| Sep 30, 2020 | -218.06% |
| Jun 30, 2020 | -93.39% |
| Mar 31, 2020 | 36.59% |
| Dec 31, 2019 | 81.70% |
| Sep 30, 2019 | -1.46% |
| Jun 30, 2019 | 75.03% |
| Mar 31, 2019 | 66.23% |
| Dec 31, 2018 | 56.75% |
| Sep 30, 2018 | -329.89% |
| Jun 30, 2018 | 197.00% |
| Mar 31, 2018 | 121.83% |
| Dec 31, 2017 | 382.22% |
| Sep 30, 2017 | 30.05% |
| Jun 30, 2017 | -176.92% |
| Mar 31, 2017 | -135.69% |